论文部分内容阅读
[目的]探讨替格瑞洛联合比伐卢定在急性冠脉综合征(ACS)患者行急诊经皮冠状动脉介入(PCI)治疗中的临床疗效及出血风险.[方法]回顾性分析2016年11月至2017年11月于湖南省脑科医院行急诊PCI术治疗的116例ACS患者的临床资料,根据其使用药物的不同将其分为观察组(n=52,术前给予替格瑞洛,术中联合比伐卢定)和对照组(n=64,术前给予替格瑞洛,术中联合普通肝素).两组患者手术前均同时给予阿司匹林口服.术中观察心肌梗死溶栓试验(TIMI)血流分级,术后观察临床疗效、比较术后7 d、1个月左室射血分数(LVEF)及左室舒张末期内径(LVDED),记录并比较两组患者主要心血管事件(MACE)及出血发生率.[结果]两组PCI植入支架数,术后7 d及1个月LVED、LVEF水平比较,差异均无统计学意义(均P >0.05);两组术前及术后TIMI 血流分级及抽吸血栓所占比例比较,差异无统计学意义(P >0.05).两组术后1个月MACE、获得性血小板减少症及支架内血栓发生率比较,差异均无统计学意义(均P >0.05);PCI术后观察组出血总发生率低于对照组,两组均为轻微出血,差异具有统计学意义(P 0.05),and there was no significant difference between the two groups in the proportion of TIMI blood flow grading and sucking thrombus before and after operation (P >0.05).There was no significant difference in the incidence of MACE,acquired thrombocytopenia and stent thrombosis between the two groups 1 month after operation (mean P >0.05),the total incidence of hemor-rhage in the observation group after PCI was lower than that in the control group,and the two groups had slight hemorrhage.The difference was statistically significant(P <0.05).[Conclusion]Tigrilol combined with bivaludine for emergency PCI treatment in ACS patients dose not increase thrombotic events within 30 days and could effectively reduce the incidence of bleeding.